The EMPA-KIDNEY trial evaluated empagliflozin’s effectiveness in patients with chronic kidney disease (CKD) at various stages of progression. Participants with an estimated glomerular filtration rate (eGFR) between 20 and less than 90 ml per minute per 1.73 m², and significant albuminuria, were randomized to receive either empagliflozin (10 mg daily) or a placebo. The primary outcomes assessed included indicators of kidney disease progression such as end-stage kidney disease, significant eGFR decline, or death from renal or cardiovascular causes.

Results from this study of 6609 patients over two years demonstrated that 13.1% in the empagliflozin group faced kidney disease progression or cardiovascular death, versus 16.9% in the placebo group, marking a notable benefit (hazard ratio 0.72). The benefits of empagliflozin were consistent across patients with or without diabetes and various eGFR ranges. The similarity in serious adverse events between both groups supports empagliflozin as a safe, effective option for mitigating CKD progression and associated cardiovascular risks.

Reference: The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.